HCQ in Resectable Localized Prostate Cancer

Inclusion Criteria: * All patients must have pathological confirmation of adenocarcinoma of the prostate Gleason score 6 (grade Group 1) or greater. * Patients must have resectable prostate cancer as defined by the AJCC (American Joint Committee on Cancer) TNM system and have planned radical prostatectomy. * Patients must have sufficient tissue from the initial diagnostic prostate biopsy, as determined by the study pathologist, to perform the required study analyses without exhausting the tissue required for clinical purposes * Age \>18 years * Adequate hematopoietic, hepatic and renal function documented prior to study entry to include: Hb. \> 10g/dL, WBC \> 3500/mm3, ANC \> 1500/mm3 and platelets \> 100,000/mm3; hepatic transaminases (AST or ALT) ≤ 2.0 times the upper limits of normal, total bilirubin ≤ 1.5 times the upper limits of normal, estimated creatinine clearance ≥ 60 mL/min or eGFR \> 60 mL/min/1.73 m2 and normal serum cations (K+/Mg2+/Ca2+) * All patients must be medically fit candidates for radical prostatectomy. * A patient with any retinopathy will only be enrolled into the study with the approval of a board-certified ophthalmologist * All patients must give informed consent indicating they are aware of the investigational nature of this study treatment prior to any study procedures being performed. Exclusion Criteria: * Patients may not have received radiation therapy for their prostate cancer. * Patients may not have received chemotherapy for their prostat…